ACON Stock Summary and Trading Ideas (Aclarion | NASDAQ:ACON)

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Aclarion trades on the NASDAQ stock market under the symbol ACON.

As of February 6, 2026, ACON stock price climbed to $2.75 with 182,627 million shares trading.

ACON has a beta of 2.23, meaning it tends to be more sensitive to market movements. ACON has a correlation of 0.05 to the broad based SPY ETF.

ACON has a market cap of $2.90 million. This is considered a Sub-Micro Cap stock.

Last quarter Aclarion reported $18,942 in Revenue and -$2.93 earnings per share. This fell short of revenue expectation by $-1,058 and missed earnings estimates by -$.29.

In the last 3 years, ACON traded as high as $342,985.70 and as low as $2.34.

The top ETF exchange traded funds that ACON belongs to (by Net Assets): VXF.

ACON has underperformed the market in the last year with a price return of -98.4% while the SPY ETF gained +15.1%. ACON has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -63.4% and -27.6%, respectively, while the SPY returned +3.3% and +0.2%, respectively.

ACON support price is $2.13 and resistance is $2.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACON shares will trade within this expected range on the day.